ATE529102T1 - Verbindung zur vorbeugung und behandlung von glaukoma - Google Patents

Verbindung zur vorbeugung und behandlung von glaukoma

Info

Publication number
ATE529102T1
ATE529102T1 AT04014078T AT04014078T ATE529102T1 AT E529102 T1 ATE529102 T1 AT E529102T1 AT 04014078 T AT04014078 T AT 04014078T AT 04014078 T AT04014078 T AT 04014078T AT E529102 T1 ATE529102 T1 AT E529102T1
Authority
AT
Austria
Prior art keywords
compound
glaucoma
prophylaxis
treatment
agent
Prior art date
Application number
AT04014078T
Other languages
English (en)
Inventor
Mitsuyoshi Azuma
Yukuo Yoshida
Mitsunori Waki
Masayoshi Uehata
Original Assignee
Senju Pharma Co
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co, Mitsubishi Tanabe Pharma Corp filed Critical Senju Pharma Co
Application granted granted Critical
Publication of ATE529102T1 publication Critical patent/ATE529102T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT04014078T 1998-08-17 1999-08-13 Verbindung zur vorbeugung und behandlung von glaukoma ATE529102T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24776298 1998-08-17
JP12296099 1999-04-28

Publications (1)

Publication Number Publication Date
ATE529102T1 true ATE529102T1 (de) 2011-11-15

Family

ID=26459997

Family Applications (3)

Application Number Title Priority Date Filing Date
AT99937073T ATE307609T1 (de) 1998-08-17 1999-08-13 Präventiva/mittel zur glaukombehandlung
AT04014077T ATE527993T1 (de) 1998-08-17 1999-08-13 Verbindung zur vorbeugung und behandlung von augen-asthenopie und pseudomyopie
AT04014078T ATE529102T1 (de) 1998-08-17 1999-08-13 Verbindung zur vorbeugung und behandlung von glaukoma

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT99937073T ATE307609T1 (de) 1998-08-17 1999-08-13 Präventiva/mittel zur glaukombehandlung
AT04014077T ATE527993T1 (de) 1998-08-17 1999-08-13 Verbindung zur vorbeugung und behandlung von augen-asthenopie und pseudomyopie

Country Status (11)

Country Link
US (2) US6673812B1 (de)
EP (3) EP1459743B9 (de)
JP (2) JP3720264B2 (de)
KR (1) KR100616466B1 (de)
CN (2) CN1195547C (de)
AT (3) ATE307609T1 (de)
AU (1) AU5198199A (de)
CA (2) CA2307285C (de)
DE (1) DE69927936T2 (de)
ES (3) ES2247822T3 (de)
WO (1) WO2000009162A1 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2334120C (en) * 1998-08-10 2006-10-17 Asahi Kasei Kogyo Kabushiki Kaisha Oral sustained-release preparation of fasudil hydrochloride
ES2295009T3 (es) 1999-03-25 2008-04-16 Mitsubishi Tanabe Pharma Corporation Inhibidores de rho quinasa para la profilaxis y el tratamiento de neumonia intersticial y fibrosis pulmonar.
WO2000057914A1 (en) * 1999-03-25 2000-10-05 Santen Pharmaceutical Co., Ltd. Ocular tension-lowering agents
US9603741B2 (en) 2000-05-19 2017-03-28 Michael S. Berlin Delivery system and method of use for the eye
WO2002024667A1 (en) 2000-09-20 2002-03-28 Merck Patent Gmbh 4-amino-quinazolines
CN100411686C (zh) * 2001-04-11 2008-08-20 千寿制药株式会社 视觉功能障碍改善剂
JP2003010158A (ja) * 2001-04-26 2003-01-14 Biochemical & Pharmacological Laboratories Inc 眼精疲労モデル、その作製方法、そのモデルを用いた評価方法およびその評価法を用いて選択された薬剤
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
DE60320933D1 (de) 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
JP4469179B2 (ja) 2002-01-23 2010-05-26 バイエル ファーマセチカル コーポレーション Ｒｈｏキナーゼ阻害剤としてのピリミジン誘導体
MXPA04007196A (es) 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
ATE546143T1 (de) 2002-08-29 2012-03-15 Santen Pharmaceutical Co Ltd Mittel zur behandlung von glaukom mit einem rho- kinase-hemmer und prostaglandinen
WO2004039366A1 (en) * 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US7972612B2 (en) 2002-11-18 2011-07-05 Santen Pharmaceutical Co., Ltd. Remedy for glaucoma comprising Rho kinase inhibitor and β-blocker
US7160894B2 (en) 2003-06-06 2007-01-09 Asahi Kasei Pharma Corporation Tricyclic compound
CN100390173C (zh) * 2003-06-06 2008-05-28 旭化成制药株式会社 3环系化合物
EP2468729B1 (de) 2003-10-15 2013-12-25 Ube Industries, Ltd. Neues Indazolderivat
WO2005053683A1 (en) 2003-11-26 2005-06-16 Duke University A method of preventing or treating glaucoma
CA2550361C (en) 2003-12-19 2014-04-29 Prabha Ibrahim Compounds and methods for development of ret modulators
US7083783B2 (en) * 2004-02-18 2006-08-01 Wisconsin Alumni Research Foundation Method for treating glaucoma
WO2005102345A1 (en) * 2004-03-30 2005-11-03 Alcon, Inc. Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
FR2868310A1 (fr) * 2004-04-02 2005-10-07 Oreal Utilisation cosmetique d'au moins un inhibiteur de la production et/ou de l'activation des rhoa kinases comme agent destine a detendre les traits et/ou decontracter la peau
WO2005118582A1 (ja) 2004-06-03 2005-12-15 Senju Pharmaceutical Co., Ltd. アミド化合物を含有する角膜知覚回復剤
TWI367098B (en) 2004-12-23 2012-07-01 Kowa Co Treating agent for glaucoma
WO2006071548A2 (en) * 2004-12-27 2006-07-06 Alcon, Inc. Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
RU2288675C2 (ru) * 2005-01-19 2006-12-10 Рудольф Алексеевич Герасимов Способ лечения псевдомиопии
WO2006088088A1 (ja) * 2005-02-16 2006-08-24 Astellas Pharma Inc. Ｒｏｃｋ阻害剤を含有する疼痛治療剤
EP1902731B1 (de) 2005-06-21 2013-04-10 Kowa Company, Ltd. Mittel zur prävention oder heilmittel für glaukom
PT1905452E (pt) 2005-07-12 2013-07-16 Kowa Co Agente para a prevenção ou tratamento do glaucoma
US8211919B2 (en) 2005-09-02 2012-07-03 Astellas Pharma Inc. Amide derivatives as rock inhibitors
US7867999B1 (en) 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
EP1962853A1 (de) 2005-12-22 2008-09-03 Alcon Research, Ltd. (indazol-5-yl)-pyrazine und (1,3-dihydro-indol-2-on)-pyrazine zur behandlung rho-kinase-vermittelter erkrankungen und leiden
WO2007142323A1 (ja) 2006-06-08 2007-12-13 Ube Industries, Ltd. 側鎖にスピロ環構造を有する新規インダゾール誘導体
BRPI0714782A2 (pt) * 2006-07-31 2013-07-16 Senju Pharma Co preparaÇço lÍquida aquosa contendo composto de amida
US20100022517A1 (en) * 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
AR064420A1 (es) 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
WO2008078762A1 (ja) 2006-12-26 2008-07-03 Santen Pharmaceutical Co., Ltd. ウレア構造を有する新規ｎ－(２－アミノフェニル)ベンズアミド誘導体
EP2135620A4 (de) 2007-03-28 2010-12-29 Santen Pharmaceutical Co Ltd Mittel gegen okuläre hypotonie mit einer verbindung zur histondeacetylasehemmung als wirkstoff
WO2008117862A1 (ja) 2007-03-28 2008-10-02 Santen Pharmaceutical Co., Ltd. ウレア構造を有する新規ピリジンカルボン酸（２－アミノフェニル）アミド誘導体
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
US8968396B2 (en) 2007-07-23 2015-03-03 Powervision, Inc. Intraocular lens delivery systems and methods of use
KR20210070407A (ko) * 2007-08-29 2021-06-14 센주 세이야꾸 가부시키가이샤 각막 내피 세포 접착 촉진제
US8372811B2 (en) * 2007-09-21 2013-02-12 Eyegene, Inc. Composition for treating retinopathy or glaucoma comprising thrombin derived peptides
US20170360609A9 (en) 2007-09-24 2017-12-21 Ivantis, Inc. Methods and devices for increasing aqueous humor outflow
JP2011513002A (ja) 2008-03-05 2011-04-28 イバンティス インコーポレイテッド 緑内障を治療する方法及び器具
US8198271B2 (en) 2008-05-23 2012-06-12 Santen Pharmaceutical Co., Ltd. Thiophenediamine derivative having urea structure
US20110130388A1 (en) * 2008-07-24 2011-06-02 Yasushi Ikuno Prophylactic or therapeutic agent for axial myopia
CN102099037A (zh) 2008-07-25 2011-06-15 旭化成制药株式会社 含有磺酰胺化合物的稳定的水溶液组合物
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
MX2011002825A (es) * 2008-09-18 2011-04-05 Astellas Pharma Inc Compuestos heterociclicos de carboxamida.
US20110125090A1 (en) * 2008-11-13 2011-05-26 Peyman Gholam A Ophthalmic drug delivery system and method
US10842669B2 (en) 2008-11-13 2020-11-24 Gholam A. Peyman Ophthalmic drug delivery method
US10272035B2 (en) * 2008-11-13 2019-04-30 Gholam A. Peyman Ophthalmic drug delivery method
KR101739994B1 (ko) 2009-04-03 2017-05-25 에프. 호프만-라 로슈 아게 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
JP5726186B2 (ja) 2009-07-09 2015-05-27 イバンティス インコーポレイテッド 眼内インプラントを送出するための単オペレータデバイス
AU2010271218B2 (en) 2009-07-09 2017-02-02 Alcon Inc. Ocular implants and methods for delivering ocular implants into the eye
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
WO2011021221A2 (en) 2009-08-17 2011-02-24 Reliance Life Sciences Pvt. Ltd. Compositions for spinal cord injury
NZ599866A (en) 2009-11-06 2014-09-26 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US8900298B2 (en) 2010-02-23 2014-12-02 Powervision, Inc. Fluid for accommodating intraocular lenses
KR20130095263A (ko) * 2010-07-27 2013-08-27 인스파이어 파마슈티컬스 인코퍼레이티드 전구약물 형태의 키나아제 저해제 화합물을 사용하여 안질환을 치료하는 방법
CN103338772A (zh) 2011-02-04 2013-10-02 兴和株式会社 用于预防或治疗青光眼的药物疗法
KR101911972B1 (ko) 2011-02-07 2018-10-25 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US8657776B2 (en) 2011-06-14 2014-02-25 Ivantis, Inc. Ocular implants for delivery into the eye
US8663150B2 (en) 2011-12-19 2014-03-04 Ivantis, Inc. Delivering ocular implants into the eye
US9358156B2 (en) 2012-04-18 2016-06-07 Invantis, Inc. Ocular implants for delivery into an anterior chamber of the eye
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
JP6193655B2 (ja) * 2012-07-13 2017-09-06 参天製薬株式会社 スルホンアミド化合物の組み合わせ
US10617558B2 (en) 2012-11-28 2020-04-14 Ivantis, Inc. Apparatus for delivering ocular implants into an anterior chamber of the eye
ES2834479T3 (es) 2013-03-15 2021-06-17 Alcon Inc Método para reconfigurar una lente intraocular para su entrega a un dispositivo de entrega
US20160339018A1 (en) 2013-04-24 2016-11-24 Kyushu University, National University Corporation Therapeutic agent for ocular fundus disease
US10709547B2 (en) 2014-07-14 2020-07-14 Ivantis, Inc. Ocular implant delivery system and method
US9844556B2 (en) 2015-03-25 2017-12-19 Megumi Honjo Preventive/therapeutic method and preventive/therapeutic agent for complications after cataract surgery
WO2017030917A1 (en) 2015-08-14 2017-02-23 Ivantis, Inc. Ocular inplant with pressure sensor and delivery system
WO2017064119A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
EP4088719A1 (de) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur behandlung von kapillarer nichtperfusion der netzhaut
US11938058B2 (en) 2015-12-15 2024-03-26 Alcon Inc. Ocular implant and delivery system
CA3086457A1 (en) 2017-12-21 2019-06-27 Santen Pharmaceutical Co., Ltd. Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor
US12029683B2 (en) 2018-02-22 2024-07-09 Alcon Inc. Ocular implant and delivery system
WO2021138331A2 (en) * 2019-12-30 2021-07-08 Memorial Sloan Kettering Cancer Center Small molecule inhibitors of ulk1
JP7708771B2 (ja) 2020-02-05 2025-07-15 ニコックス エス．エー． 緑内障及び高眼圧症の処置のための組成物
JP2024503989A (ja) 2021-01-11 2024-01-30 アルコン インコーポレイティド 粘弾性体送達のためのシステム及び方法
EP4274578A1 (de) 2021-01-11 2023-11-15 Incyte Corporation Kombinationstherapie mit jak-pfad-inhibitor und rock-inhibitor
US12245930B2 (en) 2023-06-30 2025-03-11 Alcon Inc. System and methods for compensating for intraocular lens tilt
WO2025224050A1 (en) 2024-04-22 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of patients suffering from hypomelanosis of ito

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4838677A (en) 1987-04-06 1989-06-13 Ayetech Inc. Eye exercising devices
US5250547A (en) 1991-08-29 1993-10-05 Syntex (U.S.A.) Inc. Benzopyran derivatives
DK0641781T3 (da) 1991-09-06 2000-09-18 Yoshitomi Pharmaceutical 4-Amino(alkyl)cyclohexan-1-carboxamidforbindelser og anvendelse af disse
IL104755A0 (en) 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma
US5618955A (en) 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
IL103932A (en) 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
JP3066561B2 (ja) * 1993-10-07 2000-07-17 武田薬品工業株式会社 近視予防・治療剤
JPH07133225A (ja) * 1993-11-09 1995-05-23 Santen Pharmaceut Co Ltd 毛様体筋緊張緩和剤
EP1195372A1 (de) * 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-Heterozyklisch substitutierte Benzamid Deriviate mit antihypertensiver Wirkung
JPH08198876A (ja) 1995-01-30 1996-08-06 Yoshitomi Pharmaceut Ind Ltd トランス−Ｎ−（１Ｈ−ピラゾロ〔３，４−ｂ〕ピリジン−４−イル）−４−グアニジノメチルシクロヘキサンカルボキサミド・１メタンスルホン酸塩・１水和物
US5888173A (en) 1995-08-10 1999-03-30 Singhal; Tara Chand Health saver computer break
US5906819A (en) 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
JP3421217B2 (ja) * 1995-11-20 2003-06-30 麒麟麦酒株式会社 Ｒｈｏ標的タンパク質Ｒｈｏキナーゼ
JPH09143099A (ja) * 1995-11-27 1997-06-03 Santen Pharmaceut Co Ltd 毛様体筋緊張緩和剤
PT868186E (pt) 1995-12-21 2005-05-31 Alcon Lab Inc Utilizacao de certos compostos de isoquinolinossulfonilo para tratamento de glaucoma e isquemia ocular
US5798380A (en) 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
JPH10203982A (ja) * 1996-07-05 1998-08-04 Takeda Chem Ind Ltd 視機能障害の予防・治療剤
NZ513800A (en) 1996-08-12 2001-09-28 Welfide Corp Treatment of diseases using Rho kinase inhibitors

Also Published As

Publication number Publication date
CA2635412A1 (en) 2000-02-24
EP1459743A2 (de) 2004-09-22
EP1459742B9 (de) 2012-05-02
AU5198199A (en) 2000-03-06
EP1459743A8 (de) 2005-02-02
ATE527993T1 (de) 2011-10-15
US20030125351A1 (en) 2003-07-03
EP1459742B1 (de) 2011-10-12
CA2307285C (en) 2009-03-31
EP1459743B1 (de) 2011-10-19
JP4490748B2 (ja) 2010-06-30
EP1459742A2 (de) 2004-09-22
ATE307609T1 (de) 2005-11-15
WO2000009162A1 (en) 2000-02-24
DE69927936T2 (de) 2006-06-29
EP1034793B1 (de) 2005-10-26
JP3720264B2 (ja) 2005-11-24
HK1030883A1 (en) 2001-05-25
EP1459743A3 (de) 2007-12-26
HK1069120A1 (en) 2005-05-13
US6649625B2 (en) 2003-11-18
ES2374518T3 (es) 2012-02-17
CN1287494A (zh) 2001-03-14
CN1293878C (zh) 2007-01-10
ES2247822T3 (es) 2006-03-01
CA2635412C (en) 2011-06-21
KR100616466B1 (ko) 2006-08-29
US6673812B1 (en) 2004-01-06
EP1034793A1 (de) 2000-09-13
KR20010015761A (ko) 2001-02-26
HK1069121A1 (en) 2005-05-13
ES2372572T3 (es) 2012-01-23
DE69927936D1 (de) 2005-12-01
CN1494903A (zh) 2004-05-12
JP2004277432A (ja) 2004-10-07
CN1195547C (zh) 2005-04-06
EP1459743B9 (de) 2012-08-01
CA2307285A1 (en) 2000-02-24
EP1034793A4 (de) 2003-07-09
EP1459742A3 (de) 2007-12-26

Similar Documents

Publication Publication Date Title
ATE529102T1 (de) Verbindung zur vorbeugung und behandlung von glaukoma
DE69634414D1 (de) Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie
CY1108651T1 (el) Προληπτικος ή θεραπευτικος παραγων για γλαυκωμα
BR0317020A (pt) Derivados de hidroxietilamina para o tratamento de doença de alzheimer
DE60036540D1 (de) Rho-kinase-inhibitoren für die vorbeugung oder behandlung von interstitieller pneumonie und pulmonaler fibrose
ES2139195T3 (es) Derivados de sulfonamidas como inhibidores de la aspartil-proteasa.
TNSN04082A1 (en) N,n'-substituted-1,3-diamino-2-hydroxypropane derivatives
DE19680619D2 (de) Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
BR0210241A (pt) Piranoindazóis e seu uso no tratamento de glaucoma
PT1263504E (pt) Compostos com actividade 5-ht1a uteis para o tratamento de perturbacoes da retina externa
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
DE3872701D1 (de) Prostaglandin-derivate zur behandlung von glaucoma oder augenueberdruck.
ATE359794T1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
ATE162074T1 (de) Oculare hypotensive mittel
DE69430521D1 (de) Anwendung von Prostagrandin-Analogen für die Behandlung von Glaukome und okuläre Hypertension
MXPA03012039A (es) Derivados de benzo [g]quinolina para tratar glaucoma y miopia.
ATE409491T1 (de) Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
ATE428470T1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
BR0316775A (pt) Novos análogos de benzopirano e seu uso para o tratamento de glaucoma
AU2001288053A1 (en) N-substituted benzothiophenesulfonamide derivatives
DE69905489D1 (de) Protein c zur behandlung von sichelzellanämie und thalassämie
BR0212151A (pt) Uso de compostos para tratar condições resultantes de dano ao nervo corneano após cirurgias de lasik e outras oculares ou traumas
DE50012667D1 (de) Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen
ATE314854T1 (de) Mittel zur prävention und/oder behandlung einer gewebeveränderung mesenchymalen ursprungs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties